← Human Trials & Peer-Reviewed Studies
Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome.
Plain-language guide to PMID 15853835 (2005): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 15853835
- Journal
- Clinical endocrinology
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Gravholt CH et al. (6 authors)
- DOI
- 10.1111/j.1365-2265.2005.02270.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Girls with Turner syndrome (TS) receive GH treatment during childhood, and in adolescence this treatment may be combined with oestradiol.
Who Took Part
The age groups tagged for this paper are teenagers, women only.
Twenty-four-hour sampling of oestradiol, growth factors, insulin, glucose, lipolytic and gluconeogenic precursors was performed, followed by an oral glucose tolerance test (OGTT) and assessment of body composition and mineral content.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
The researchers performed a double-blind, placebo-controlled, randomized, crossover study.
What Was Measured
The subject headings attached to it are Blood Glucose, Body Composition, Bone Density, Case-Control Studies, Estradiol, Glucagon and Glucose Tolerance Test.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.